Roth Capital Upgrades ACAD to $11 - Strong Efficacy Supports 1 Billion Potential. LINK
wall street cheat sheet
Analysts: CBS May Buy Back Shares and 4 More Research Notes to Review Now
By Leah Powell | More Articles
March 14, 2013
Page 1 of 5
Acadia Pharmaceuticals (NASDAQ:ACAD): Roth Capital is convinced that a Phase III trial of ACADIA’s pimavanserin for psychosis in Parkinson’s disease showed strong efficacy results supporting the $1 billion potential for the drug. The firm keeps its Buy rating and an $11 price target on the stock.
FDA should give them the new priority designation for Alzheimer's since there is such a need for effective new treatments. Also, if Pim is approved for Parkinson's the bar for Alzheimer's will be lower since this will just be a new indication for an already approved drug. Same deal for Schizophrenia although management seemed to indicate Alz was more similar to Park than Schiz.